News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
21
2026
-
04
Powerful Partnership, Ushering in a New Journey: Linuo Pharmaceutical and Hubei General Pharmaceutical Co., Ltd. Sign a Strategic Cooperation Agreement
Classification：
Corporate News
On April 21, Shandong Linuo Pharmaceutical Co., Ltd., a wholly owned subsidiary of Shandong Keyuan Pharmaceutical Co., Ltd. (stock code: 301281.SZ), and Hubei General Pharmaceutical Co., Ltd. held a grand signing ceremony for a strategic cooperation agreement. The two companies, leveraging their respective strengths and complementing each other’s advantages, will deepen comprehensive collaboration in areas such as product distribution, supply-chain synergy, and coverage of medical end-users, thereby pooling resources to support the “Healthy China” initiative and jointly forge a new paradigm for high-quality development of the pharmaceutical industry.
Li Hongfu, Chairman of Keyuan Pharmaceutical and Linuo Pharmaceutical, Yu Shijun, Secretary of the Party Branch, Director, and General Manager of Hubei General Pharmaceutical, along with relevant officials from both sides, attended and witnessed the signing ceremony.
Hubei General Pharmaceutical is a core regional platform under China General Technology Group and China National Pharmaceutical Group, deeply engaged in the pharmaceutical and healthcare industry. It boasts a well-established distribution network, extensive market coverage, and outstanding industry credibility. Linuo Pharmaceutical is a wholly owned subsidiary of Keyuan Pharmaceutical, a leading enterprise in China’s specialized segment of chemical active pharmaceutical ingredients. The company focuses on the R&D, manufacturing, and sales of pharmaceutical products, with a robust product portfolio spanning cardiovascular, psychotropic and neurological, diabetic, anti-inflammatory and antibacterial, and respiratory therapeutic areas. It has established a diversified product lineup that covers multiple dosage forms, including solid preparations, injectables, oral solutions, drops, liniments, pastes, and sprays.
The two parties’ respective resource advantages are highly complementary, and this strategic cooperation will usher in a new chapter of synergistic development across the pharmaceutical industry—encompassing manufacturing, distribution, and trade. Under the agreement, the two sides will focus on deepening collaboration in three key areas: first, expanding product distribution networks and leveraging their respective platform strengths to achieve nationwide coverage; second, strengthening supply-chain coordination to streamline the entire value chain and share high-quality resources; and third, intensifying engagement at the clinical front line to ensure that premium medicines reach end-users directly and benefit the general public.
In his address, Chairman Li Hongfu stated that Hubei General Pharmaceutical is a strong, reliable, and outstanding partner. Lino Pharmaceutical will deepen cooperation with the utmost sincerity, superior service, and stable supply, leveraging Hubei General’s well-established distribution network to ensure efficient access of high-quality pharmaceutical products to end-users, and jointly set a benchmark for collaboration between central and local pharmaceutical enterprises.
A powerful alliance ushers in a new chapter, with united efforts to build a shared vision of health. The signing of this strategic cooperation agreement marks the entry of our collaboration into a new phase of substantive implementation. Moving forward, Linuo Pharmaceutical and Hubei General Pharmaceutical will uphold the principles of integrity, mutual benefit, pragmatism, and efficiency, establish a long-term cooperative mechanism, and steadily advance the realization and impact of all collaborative initiatives. By leveraging stronger synergy, superior services, and higher quality, we will contribute to the continued advancement of China’s pharmaceutical and healthcare sector.
Related news
2026-05-18
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating smart manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed high praise for the company’s practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China